Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.
In positive interim analysis results from the phase 3 trial ECHO, acalabrutinib (Calquence; AstraZeneca) in combination with standard of care chemoimmunotherapy—bendamustine and rituximab—demonstrated both statistically significant and clinically meaningful improvement in progression-free survival (PFS) in adult patients with previously untreated mantle cell lymphoma (MCL) compared with standard of care alone. Acalabrutinib is a next-generation, selective inhibitor of Bruton tyrosine kinase (BTK) that binds covalently to BTK to hinder its activity. BTK signaling results in the activation of pathways that are necessary for B-cell proliferation, trafficking, chemotaxis, an adhesion within B cells.